Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:198 (26 July), doi:10.1136/bmj.327.7408.198
Elizabeth Rees, research nurse in palliative care1, Janet Hardy, consultant in palliative care1
1 Department of Palliative Medicine, Royal Marsden Hospital, Sutton, Surrey SM2 5PT
Correspondence to: J Hardy
Objectives To develop a process of advance consent to enable research to be undertaken in patients in the terminal phase.
Design Feasibility study of an advance consent process to support a randomised controlled trial of two antimuscarinic drugs (hyoscine hydrobromide and glycopyrronium bromide) in the management of noisy respirations associated with retained secretions ("death rattle").
Setting Palliative care wards in a major cancer centre.
Participants Patients admitted to a palliative care ward who may develop "death rattle" and thus be eligible for randomisation.
Main outcome measures Patient accrual; acceptability of the consent process.
Results Of the 107 patients approached, 58 patients gave advance consent to participate in the study. Of these, 15 patients developed death rattle and were randomised to receive either hyoscine or glycopyrronium; 16 patients died elsewhere; 15 patients died on the palliative care wards but were not randomised; 12 patients are still alive.
Conclusions Initial assessment suggests that this is a workable consent process allowing research to be undertaken in patients who are unable to give consent at the time of randomisation. Patient accrual rates to date are lower than needed to recruit adequate numbers in the time allotted to answer the research question.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses